VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

October 6, 2017: By Jon Swedien
VSY's AcrivaUD Trinova Trifocal IOL

VSY’s AcrivaUD Trinova Trifocal IOL

VSY Biotechnology announced Oct. 2 it planned to launch its AcrivaUD Trinova Trifocal IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, being held Oct. 7-11 in Lisbon, Portugal.

The AcrivaUD (Ultra-Definition) Trinova, which has CE mark approval, is manufactured with VSY’s seamless vision technology (SVT).

SVT is a unique patent pending technique to produce an IOL optical surface that does not exhibit any sharp edges, helping reduce halos and scattered light, the company said. The lens shape is derived from sinusoidal functions and results in smoothly, varying surface profiles.

The Netherlands-based firm said the design provides the highest and most optimum light distribution, better contrast sensitivity, and enhanced depth of focus for spectacle independence at all distances.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility